A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
Principal Investigator
Anthony TraboulseeOverview
Body Locations and Systems
Multiple SclerosisClinicalTrials.gov#
NCT02545868Status
Closed for RecruitmentStudy Start/End
Feb 18, 2016 to Feb 28, 2020Locations
UBC Hospital, Vancouver General Hospital
Name/Title
Research CoordinatorPhone
604-822-1756Purpose of Study
This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT], 23-valent pneumococcal polysaccharide vaccine [23-PPV], influenza vaccine, and keyhole limpet hemocyanin [KLH]) after administration of a dose of ocrelizumab (OCR) in participants with relapsing multiple sclerosis (RMS).
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.